| Understanding the effectiveness of government interventions against the resurgence of COVID-19 in Europe M Sharma, S Mindermann, C Rogers-Smith, G Leech, B Snodin, J Ahuja, ... Nature communications 12 (1), 5820, 2021 | 171 | 2021 |
| Mask wearing in community settings reduces SARS-CoV-2 transmission G Leech, C Rogers-Smith, JT Monrad, JB Sandbrink, B Snodin, R Zinkov, ... Proceedings of the National Academy of Sciences 119 (23), e2119266119, 2022 | 85* | 2022 |
| RNA vaccines: a suitable platform for tackling emerging pandemics? JB Sandbrink, RJ Shattock Frontiers in Immunology 11, 608460, 2020 | 73 | 2020 |
| Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19 M Sharma, S Mindermann, C Rogers-Smith, G Leech, B Snodin, J Ahuja, ... MedRxiv, 2021.03. 25.21254330, 2021 | 50 | 2021 |
| Promoting versatile vaccine development for emerging pandemics JT Monrad, JB Sandbrink, NG Cherian npj Vaccines 6 (1), 26, 2021 | 34 | 2021 |
| Altered glycolysis triggers impaired mitochondrial metabolism and mTORC1 activation in diabetic β-cells E Haythorne, M Lloyd, J Walsby-Tickle, AI Tarasov, J Sandbrink, I Portillo, ... Nature communications 13 (1), 6754, 2022 | 28 | 2022 |
| Biosecurity in an age of open science JA Smith, JB Sandbrink PLoS biology 20 (4), e3001600, 2022 | 21* | 2022 |
| Artificial intelligence and biological misuse: Differentiating risks of language models and biological design tools JB Sandbrink arXiv preprint arXiv:2306.13952, 2023 | 19 | 2023 |
| Biosecurity risks associated with vaccine platform technologies JB Sandbrink, GD Koblentz Vaccine 40 (17), 2514-2523, 2022 | 15 | 2022 |
| Rapid proliferation of pandemic research: implications for dual-use risks S Musunuri, JB Sandbrink, JT Monrad, MJ Palmer, GD Koblentz Mbio 12 (5), 10.1128/mbio. 01864-21, 2021 | 13 | 2021 |
| A dataset of non-pharmaceutical interventions on SARS-CoV-2 in Europe G Altman, J Ahuja, JT Monrad, G Dhaliwal, C Rogers-Smith, G Leech, ... Scientific Data 9 (1), 145, 2022 | 11 | 2022 |
| Insidious Insights: Implications of viral vector engineering for pathogen enhancement JB Sandbrink, EC Alley, MC Watson, GD Koblentz, KM Esvelt Gene Therapy 30 (5), 407-410, 2023 | 10 | 2023 |
| Protocols and risks: when less is more J Pannu, JB Sandbrink, M Watson, MJ Palmer, DA Relman Nature protocols 17 (1), 1-2, 2022 | 10 | 2022 |
| Safety and security concerns regarding transmissible vaccines JB Sandbrink, MC Watson, AM Hebbeler, KM Esvelt Nature Ecology & Evolution 5 (4), 405-406, 2021 | 10 | 2021 |
| Differential technology development: A responsible innovation principle for navigating technology risks J Sandbrink, H Hobbs, J Swett, A Dafoe, A Sandberg Available at SSRN 4213670, 2022 | 8 | 2022 |
| Improved understanding of biorisk for research involving microbial modification using annotated sequences of concern GD Godbold, FC Hewitt, AD Kappell, MB Scholz, SL Agar, TJ Treangen, ... Frontiers in Bioengineering and Biotechnology 11, 1124100, 2023 | 6 | 2023 |
| Mitigating biosecurity challenges of wildlife virus discovery J Sandbrink, J Ahuja, J Swett, G Koblentz, C Standley Available at SSRN 4035760, 2022 | 6* | 2022 |
| Beyond Biosecurity by Taxonomic Lists: Lessons, Challenges, and Opportunities P Millett, T Alexanian, KR Brink, SR Carter, J Diggans, MJ Palmer, ... Health security 21 (6), 521-529, 2023 | 4 | 2023 |
| Innovate and stockpile: respiratory protection for essential workers in a catastrophic pandemic NX Montazeri, JB Sandbrink Health security 21 (4), 266-271, 2023 | 2 | 2023 |
| Widening the framework for regulation of dual-use research in the wake of the COVID-19 pandemic JB Sandbrink, S Musunuri, JT Monrad | 2 | 2021 |
Joshua Teperowski MonradOxford UniversityBestätigte E-Mail-Adresse bei philosophy.ox.ac.uk
